Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,519.12
(
0.61%
)
US TECH 100
29,405.20
(
0.66%
)
Dow Jones
50,461.68
(
0.00%
)
Brent Oil
94.10
(
-2.97%
)
Bitcoin
75,637.75
(
-0.27%
)
News Focus
News Focus
Post# of 257644
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

acgood

Send PM Follow Ignore
Followers 17
Posts 1093
Boards Moderated 0
Alias Born 05/12/2007

acgood

Re: jq1234 post# 142643

Friday, 05/25/2012 9:53:18 PM

Friday, May 25, 2012 9:53:18 PM

Post# of 257644
Interesting that both ALNY and ISIS act confidently that the TTR composite surrogate endpoint employed for tafamidis will be acceptable for their respective pivotal trials. Maybe not so definite?

Opinions and comments may have been previously posted @BioDueDiligence, at www.biotechduediligence.com, or disseminated to Chimera Research Group subscribers.

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today